Detalles de la búsqueda
1.
Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease.
J Card Fail
; 25(2): 78-86, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30423457
2.
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
J Am Soc Nephrol
; 29(11): 2755-2769, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30314978
3.
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
JAMA
; 321(1): 69-79, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30418475
4.
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
Cardiovasc Diabetol
; 17(1): 39, 2018 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29540217
5.
Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes.
Pharmacogenet Genomics
; 27(4): 135-142, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28134748
6.
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Diseaseã- Results From EMPA-REG OUTCOME®.
Circ J
; 81(2): 227-234, 2017 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-28025462
7.
Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.
Diabetologia
; 59(4): 700-8, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26704626
8.
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Am J Kidney Dis
; 66(3): 441-9, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25960304
9.
Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.
Cardiovasc Diabetol
; 14: 57, 2015 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25990013
10.
Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin.
Diabetologia
; 57(9): 1869-75, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24906949
11.
Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
Lancet
; 382(9902): 1413-23, 2013 Oct 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-23948125
12.
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
Cardiovasc Diabetol
; 13: 28, 2014 Jan 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-24475922
13.
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
Cardiovasc Diabetol
; 13: 102, 2014 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-24943000
14.
Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study.
Endocr Pract
; 20(5): 412-20, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24326003
15.
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Lancet
; 380(9840): 475-83, 2012 Aug 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-22748821
16.
Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials.
Cardiovasc Diabetol
; 12: 60, 2013 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-23570327
17.
Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
Br J Clin Pharmacol
; 76(3): 445-54, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23331248
18.
Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes.
Am J Ther
; 20(6): 618-21, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23411609
19.
Pharmacodynamics, safety, tolerability and pharmacokinetics of a single oral dose of an engineered phenylalanine ammonia-lyase in patients with phenylketonuria.
Mol Genet Metab Rep
; 37: 101012, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38053938
20.
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.
Cardiovasc Diabetol
; 11: 3, 2012 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-22234149